Literature DB >> 9290082

Radioiodinated antibody targeting of the HER-2/neu oncoprotein.

F J Xu1, Y H Yu, D S Bae, X G Zhao, S K Slade, C M Boyer, R C Bast, M R Zalutsky.   

Abstract

The HER-2/neu oncogene encodes a 185 kDa phosphoglycoprotein that is overexpressed in breast, ovarian and other cancers. Seven monoclonal antibodies reactive with oncoprotein were labeled with 131I. In vitro experiments with SKOv3 9002-18 cells determined binding affinity, internalization and degradation. The biodistribution of these antibodies in comparison to 125I-labeled nonspecific antibody was measured in athymic mice with SKOv3 9002-18 ovarian carcinoma xenografts. Antibody 520C9 exhibited the highest and most specific retention in tumor, peaking at 17.4 +/- 5.6% ID/g at 24 h.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9290082     DOI: 10.1016/s0969-8051(97)00065-6

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  4 in total

1.  Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.

Authors:  Zhengyuan Zhou; Ganesan Vaidyanathan; Darryl McDougald; Choong Mo Kang; Irina Balyasnikova; Nick Devoogdt; Angeline N Ta; Brian R McNaughton; Michael R Zalutsky
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

2.  Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.

Authors:  Torun Engfeldt; Anna Orlova; Thuy Tran; Alexander Bruskin; Charles Widström; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-05       Impact factor: 9.236

3.  Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.

Authors:  Tove Olafsen; David Betting; Vania E Kenanova; Felix B Salazar; Pat Clarke; Jonathan Said; Andrew A Raubitschek; John M Timmerman; Anna M Wu
Journal:  J Nucl Med       Date:  2009-08-18       Impact factor: 10.057

4.  Preclinical characterisation of 111In-DTPA-trastuzumab.

Authors:  Marjolijn N Lub-de Hooge; Jos G W Kosterink; Patrick J Perik; Hugo Nijnuis; Ly Tran; Joost Bart; Albert J H Suurmeijer; Steven de Jong; Pieter L Jager; Elisabeth G E de Vries
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.